The Lancet Haematology (@thelancethaem) 's Twitter Profile
The Lancet Haematology

@thelancethaem

The Lancet Haematology is a world-leading #haematology journal publishing peer-reviewed research and reviews, opinion, and news. #hematology

ID: 2596297298

linkhttps://www.thelancet.com/journals/lanhae/home calendar_today30-06-2014 12:36:10

4,4K Tweet

20,20K Followers

1,1K Following

The Lancet Haematology (@thelancethaem) 's Twitter Profile Photo

🔥Just presented at #EHA2025! Dr. Elias Jabbour presented promising safety & activity of subcutaneous #blinatumomab in relapsed/refractory ALL ✔️ Two dose regimens tested 💉 Phase 2 dose selected 🏠 Potential for homecare, no central line needed 👇 tinyurl.com/5ckwe6e5

🔥Just presented at #EHA2025! 

Dr. Elias Jabbour presented promising safety & activity of subcutaneous #blinatumomab in relapsed/refractory ALL

✔️ Two dose regimens tested
💉 Phase 2 dose selected
🏠 Potential for homecare, no central line needed

👇
tinyurl.com/5ckwe6e5
Eddie Cliff (@eddie_cliff) 's Twitter Profile Photo

Listening for the journey home - new The Lancet Haematology podcast featuring a discussion of our commission on adverse events in haematology open.spotify.com/episode/5kT1Ya… #EHA2025

Listening for the journey home - new <a href="/TheLancetHaem/">The Lancet Haematology</a> podcast featuring a discussion of our commission on adverse events in haematology 

open.spotify.com/episode/5kT1Ya…

#EHA2025
The Lancet Haematology (@thelancethaem) 's Twitter Profile Photo

🛫On your way to #18ICML in Lugano? Daniela Marín-Hernández, Senior Editor, invites you to reach out with enquiries. Explore our scope, reach & impact, commitment to publishing excellence, & more: hubs.ly/Q01McRRH0

🛫On your way to #18ICML in Lugano? 

Daniela Marín-Hernández, Senior Editor, invites you to reach out with enquiries. 

Explore our scope, reach &amp; impact, commitment to publishing excellence, &amp; more: hubs.ly/Q01McRRH0
The Lancet Haematology (@thelancethaem) 's Twitter Profile Photo

📢Final BELLINI results at 45.6 months follow-up show no overall survival benefit of venetoclax in the general relapsed or refractory multiple myeloma population. Post-hoc analyses suggest benefits are limited to biomarker-positive subgroups. 👇 shorturl.at/bwOYn

Kai Rejeski (@krejeski) 's Twitter Profile Photo

Can off-the-shelf iPSC-derived NK cells change the game for B-cell lymphoma? Tobias Tix and I had the opportunity to reflect on an early-phase study by Strati et al, published in The Lancet Haematology , studying FT516—a non-CAR-bearing, iPSC-derived NK-cell Tx. thelancet.com/journals/lanha…

The Lancet Haematology (@thelancethaem) 's Twitter Profile Photo

🩸July issue! Trials on avatrombopag for ITP, NK-cell therapy for R/R B-cell lymphoma, bexmarilimab+azacitidine for MDS & R/R AML & SC blinatumomab for R/R B-cell acute lymphoblastic leukaemia Cover on lymphoma collaborative groups! Issue here 👉shorturl.at/9645R

🩸July issue!   

Trials on avatrombopag for ITP, NK-cell therapy for R/R B-cell lymphoma, bexmarilimab+azacitidine for MDS &amp; R/R AML &amp; SC blinatumomab for R/R B-cell acute lymphoblastic leukaemia  

Cover on lymphoma collaborative groups!  

Issue here 👉shorturl.at/9645R